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Since organ transplantation became routine more than three
decades ago, there has been a need to obtain useful infor-
mation regarding graft health, with assessment of the pre-
sence of progressive immune-mediated graft rejection of
particular importance for planning intervention. Although
the recommended method is to obtain sequential biopsies
from the graft itself, this procedure is invasive and risky,
particularly if more than one sample is needed. Therefore,
identification of less invasive markers, ideally measureable
in the blood of transplant recipients, has been actively
investigated. Because of the large number of losses of
pancreatic grafts, it is particularly important to discover
surrogate markers of immune rejection.
In this issue of Digestive Diseases and Sciences, Dong
et al. [1] describe a porcine model of pancreaticoduodenal
transplantation with or without immunosuppression that
was used to evaluate the effectiveness of three potential
peripheral blood biomarkers of acute rejection for up to
seven days post-transplant. The authors selected intercel-
lular adhesion molecule (ICAM)-1, Fas cell surface death
receptor (Fas), and its ligand FasL, all reported previously
to be involved in the acute rejection response after solid
organ transplantation in humans and in animal models.
ICAM-1 is an adhesion molecule involved in firm
endothelial adhesion and trans-endothelial migration of
leukocytes, including T cells, monocytes, and neutro-
phils, at sites of immune response and immunological
synapse formation (reviewed elsewhere [7]). ICAM-1 is
constitutively expressed on the surface of human endo-
thelial cells and its expression is increased in the presence
of pro-inflammatory cytokines including tumor necrosis
factor (TNF)-a, interferon (IFN)-c and interleukin (IL)-1b.
The most important ligand for ICAM-1 is the b-2 integrin
lymphocyte function-associated (LFA)-1 (aLb2); it is
expressed on all types of leukocyte but requires a Ca2?-
dependent conformational change before binding. Impor-
tantly, ICAM-1 expression on the surface of cardiac
endothelium is increased as a consequence of rejection of
human cardiac allografts [11] and has also been identified
in pancreatic allografts [13]. The presence of the soluble
form and antibodies to ICAM-1 have also been detected in
the serum of these patients [3, 6]. Moreover, the functional
relevance of increased ICAM-1 expression during rejection
has been demonstrated using ICAM-1 knockout mice in
models of heterotopic cardiac transplantation [5] whereas
in a rat pancreas transplant model, treatment with anti-
ICAM-1 antibodies attenuated acute allograft rejection [9].
Fas, also known as CD95 or Apo-1, is sometimes termed
a ‘‘death receptor’’ because it can induce apoptosis in the
cells on which it is expressed, after ligation by its cell-
surface ligand FasL, highly regulated expression of which
occurs on the surface of effector T cells. Expression of Fas
and FasL have been identified in biopsies during acute
rejection of cardiac allografts [8]. Furthermore, FasL
induces tolerance in a number of transplant models
including pancreatic islet models, after overexpression of
the soluble protein [2, 4].
Dong et al. [1] found that all three molecules have
potential as early indicators of acute rejection of pancreatic
allografts; this must now be confirmed in biopsies and in
the circulation of pancreatic transplant recipients. Their
development of this porcine model suggests it could be a
useful human correlate with potential for future discovery
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of increasingly sophisticated diagnostic biomarkers, but
also as a model in which to trial novel anti-rejection
therapeutics.
Since ICAM-1–LFA-1 interactions are involved in leu-
kocyte firm adhesion to the endothelium and subsequent
trans-endothelial migration and in immunological synapse
formation, blocking the early post-transplant ICAM-1–
LFA-1 interactions between recipient leukocytes and graft
vascular endothelial cells could potentially reduce the
opportunities for reactive donor T cells to infiltrate the graft
and become activated. Such an approach could therefore
ultimately reduce acute rejection with the potential to
induce tolerance of the transplanted graft. Thus, several
years ago, there was a flurry of interest in the therapeutic
use of antibodies to ICAM-1 to prevent acute and chronic
allograft rejection. Results from initial animal studies were
promising, although it was later reported that blocking
antibodies to ICAM-1 themselves activated human neu-
trophils [12] and did not prevent acute rejection in a renal
transplant trial [10].
Identification of increased expression of ICAM-1 pre-
ceding histopathologic signs of acute rejection in the
transplanted pancreas, and, simultaneously, its increased
expression in circulating leukocytes, immediately suggests
a new possibility of preventing acute allograft rejection.
Given recent advances in gene therapy, in particular
development of small interfering RNA (siRNA) technology
coupled with more efficient viral and non-viral approaches
to gene transfer, it may be possible, in the not too distant
future, to knock down ICAM-1 expression in donor
endothelial cells and in recipient peripheral blood T lym-
phocytes before transplantation. Such an approach is
attractive, because it may not only prevent acute rejection
but could also affect chronic vascular rejection, thus
improving long-term graft survival and, therefore, patient
care.
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